You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 6, June 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Ocular/ Adnexal Tumors
 •Pediatric Ophthalmology
 •Retinal/ Chorioretinal Disorders
 •Pediatrics
 •Pediatrics, Other
 •Drug Therapy
 •Adverse Effects
 •Hematology/ Hematologic Malignancies
 •Hematology, Other
 •Alert me on articles by topic

The Adverse Events of Chemotherapy for Retinoblastoma

What Are They? Do We Know?

Allison E. Rizzuti, BA; Ira J. Dunkel, MD; David H. Abramson, MD

Arch Ophthalmol. 2008;126(6):862-865.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

External beam radiation (EBR) is an effective treatment for intraocular retinoblastoma, as it has been shown to save children's vision as well as their lives. While once standard therapy, and despite its success, EBR has largely been abandoned, owing to the concern of secondary malignancies,1 and has been replaced with systemic multiagent chemotherapy. It is unusual in cancer treatment that the decision for successful treatment be based not on the immediate result (eliminating the cancer), but rather on complications that may develop many (> 30) years later. Nonetheless, in the last 10 years there has been a shift in treatment preference, and numerous authors have reported favorable outcomes using various drug regimens.2-13 It has been demonstrated that Reese-Ellsworth groups I-V can be successfully treated with either EBR or multiagent systemic chemotherapy followed by focal treatments. Patient and ocular survival . . . [Full Text of this Article]


AUTHOR INFORMATION






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.